Who
Peter J. Graham
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, ADC Therapeutics SA; EVP General Counsel, Secretary, Antares Pharma; EVP; General Counsel, Delcath Systems; SVP - Chief Legal Officer, E-Z-Em; Director, AngioDynamics.
In numbers
- Trades disclosed
- 87
- Buys
- 1
- Sells
- 1
- Bought
- $15K
- Sold
- $222K
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 18 Jan 2006
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —221,100 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —221,100 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | $1.2M294,800 at $3.99 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $133K33,294 at $3.99 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | $1.2M294,800 at $3.99 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $133K33,294 at $3.99 | filing |
| 6 Dec 2025filed 9 Dec 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $163K49,508 at $3.29 | filing |
| 13 Feb 2025filed 14 Feb 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | $354K220,000 at $1.61 | filing |
| 6 Dec 2024filed 9 Dec 2024 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $130K41,458 at $3.13 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharmaoption or derivative | SEC FORM 4 Code D | —125,000 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharmaoption or derivative | SEC FORM 4 Code D | —212,900 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharmaoption or derivative | SEC FORM 4 Code D | —217,725 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharmaoption or derivative | SEC FORM 4 Code D | —177,453 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharmaoption or derivative | SEC FORM 4 Code D | —170,227 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharmaoption or derivative | SEC FORM 4 Code D | —254,165 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharmaoption or derivative | SEC FORM 4 Code D | —163,963 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharma | SEC FORM 4 Code D | $2.3M414,470 at $5.60 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharma | SEC FORM 4 Code D | $1.1M202,139 at $5.60 | filing |
| 24 May 2022filed 26 May 2022 | Antares Pharma | SEC FORM 4 Code D | $696K124,234 at $5.60 | filing |
| 3 Mar 2022filed 4 Mar 2022 | Antares Pharma | SEC FORM 4 Code A | —26,044 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.